460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)

• Jennifer Wang,
• Ramona Dadu,
• Naifa L Busaidy,
• Anastasios Maniakas,
• Sarah Hamidi,
• Priyanka C Iyer,
• Maria K Gule-Monroe,
• Mark E Zafereo,
• Maria E Cabanillas

Affiliations

Jennifer Wang

1 Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, California, USA

Ramona Dadu

Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA

Naifa L Busaidy

Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA

Anastasios Maniakas

Head & Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Sarah Hamidi

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Priyanka C Iyer

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Maria K Gule-Monroe

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Mark E Zafereo

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Maria E Cabanillas

University of Texas MD Anderson Cancer Center, Houston, TX, USA